Retatrutide Research Overview
A comprehensive overview of retatrutide — a triple agonist targeting GLP-1, GIP, and glucagon receptors — and its current research landscape.
Scientific background / literature overview only. Discussion of published research does not describe the intended use of Novex Peptide products.
Introduction
Retatrutide is a synthetic peptide that functions as a triple agonist, targeting three metabolic receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple pharmacological profile has made it a compound of significant research interest in metabolic studies.
> **Research Context Notice** — This article summarises published scientific literature for educational and research-reference purposes only. Discussion of experimental, preclinical or clinical findings does not represent a permitted use of Novex Peptide products. Products supplied by Novex Peptide are intended exclusively for in-vitro laboratory research and are not intended for human or animal administration.
Mechanism of Action
Retatrutide activates three G-protein coupled receptors simultaneously:
GLP-1 Receptor Agonism
Activation of the GLP-1 receptor influences glucose homeostasis and gastric emptying in experimental systems.
GIP Receptor Agonism
GIP receptor activation contributes to glucose-dependent insulin secretion in experimental systems.
Glucagon Receptor Agonism
Glucagon receptor activation affects hepatic glucose production and lipid metabolism in preclinical models.
The combined activation of all three receptors produces effects that differ from single or dual agonists, which is the basis for ongoing research interest.
Current Research
Preclinical Studies
Published preclinical literature includes in-vivo animal studies investigating retatrutide's effects on metabolic endpoints. References to such studies are provided solely as scientific background and do not indicate that Novex Peptide products are supplied for animal administration.
Clinical Research
Published clinical investigations have evaluated retatrutide in relation to metabolic endpoints, including changes in body weight. These findings relate to investigational clinical research and do not describe an intended use of material supplied by Novex Peptide.
Chemical Properties
Storage Considerations
Follow the supported product label and compound-specific laboratory protocol. Solution stability depends on the exact material, solvent, concentration and storage conditions; there is no universal refrigerated shelf life or freezing protocol. Obtain missing stability information before preparation. Where validated, use aliquots to minimise repeated freeze-thaw cycles.
Testing Methods
Retatrutide batches should be verified by:
Research Limitations
Retatrutide is supplied for in-vitro laboratory research only. Published preclinical and clinical trial findings are experimental. No medical, therapeutic, or dosing claims are made or implied. Retatrutide is not approved for human therapeutic use by any regulatory authority. References to in-vivo animal studies in the published literature are provided solely as scientific background and do not indicate that Novex Peptide products are supplied for animal administration.
References
The following references are provided for researchers seeking to review the primary literature. They do not constitute an endorsement of any therapeutic application.
References
- 1.Jastreboff AM, et al. Retatrutide for Obesity. N Engl J Med. 2023;389(6):514-526.
- 2.Ceperuelo-Mallafré V, et al. Triple GLP-1/GIP/Glucagon Agonism. Trends Endocrinol Metab. 2023;34(5):287-298.
- 3.Coskun T, et al. Retatrutide Pharmacology. Mol Metab. 2022;57:101433.
Research use only. This article is for educational purposes only and does not constitute advice for any application involving human use. No medical claims are made.
